Aquapharm Bio – Discovery Ltd (Aquapharm), a leading UK marine biotechnology company developing, amongst other things, anti-infective drug candidates from marine natural products, is pleased to announce the completion this month of its latest round of financing.
The investment of £344000 by E-Synergy Ltd and the Scottish Enterprise Co-Investment Fund completed the £1.25 million package by adding to a recent earlier investment of £350000 (£175,000 each) by NESTA (the National Endowment for Science, Technology and the Arts) and Argyll & the Islands Enterprise (AIE), and thereby paving the way for a future equity investment of £253,400 and grants of up to £300000 from AIE.
Aquapharm was formed in 2000 by Dr Andrew Mearns Spragg & Dr Kathryn Fraser, and is one of the first UK marine biotechnology companies. This funding round has allowed it to expand into new bespoke laboratory facilities within the European Centre for Marine Biotechnology (ECMB), which is situated beside the sea near Oban in Argyll. The Company currently employs a team of 9 full-time staff and has recently strengthened the management team with the addition of three new non-executive directors.
Joseph Meaney | alfa
Successful calculation of human and natural influence on cloud formation
04.11.2016 | Goethe-Universität Frankfurt am Main
Invasive Insects Cost the World Billions Per Year
04.10.2016 | University of Adelaide
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Life Sciences
08.12.2016 | Physics and Astronomy
08.12.2016 | Materials Sciences